The study was conducted in November 2020. 54 male participants, diagnosed with HIV, were eligible for the study.
They received two doses of Oxford Astra-Zeneca vaccine.
The study found the vaccine to be effective and safe for those living with HIV.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
18 June 2021
Sandra Adele (cohort 2019-2020) co-authored this paper on the efficacy of the Oxford Astra-Zeneca vaccine for the 40 million people globally living with HIV. This study aimed to assess the vaccine’s ability to stimulate an immune response on those who have their immunity compromised.